VISIUS® Surgical Theatre iMRI brings increased tumor resection and limits
MINNEAPOLIS, MN, June 12, 2013 /CNW/ - IMRIS Inc. (NASDAQ: IMRS; TSX:
IM) ("IMRIS" or the "Company") today announced that University Hospital
Tübingen neurosurgeons in Tübingen, Germany, are reporting success
toward their objectives of limiting patient risk and improving surgical
precision using intraoperative MRI for brain surgery procedures in the
VISIUS® Surgical Theatre since its June 2011 installation.
"Using intraoperative MRI in the VISIUS Surgical Theatre has enabled us
to perform more resection and more complete tumor tissue removal
without increasing the patient's risk of new neurological deficits,"
said Dr. Constantin Roder, a neurosurgeon at University Hospital
Tübingen. "In some cases," he added, "we've been able to see and remove
tumor-residuals that wouldn't have been possible without iMRI."
More than 150 procedures, primarily gliomas and pituitary tumors and
other types of skull-based neurosurgeries, have been conducted in the
Tübingen iMRI suite. After 100 cases, the hospital neurosurgical team
states no adverse events or patient safety issues related to the iMRI
have occurred, according to a review article in the Theatre and Surgery
section of the current issue of Hospital Healthcare 2013. "Not moving
the patient during surgery is an important part of minimizing patient
risk," Roder said.
Retrospective analysis of patients after iMRI-guided resection of
pituitary tumors (adenomas) shows that total resections improved in
approximately 30 percent of the cases.1,2 Roder states that the total resection experience of Tübingen
neurosurgeons with 16 difficult pituitary adenomas was improved in up
to 63 percent of the cases. In addition, iMRI use could be attributed,
he said, to improved precision and preservation when tumors are located
near sensitive areas or critical anatomical structures.
Roder also stated that the number of total resections of glioblastomas
was improved significantly by iMRI-guided surgery compared with
conventional surgery as was expected based on published evidence. A
safe total resection of high-grade gliomas, he added, is known to be
one of the most important prognostic factors to expand survival in
The VISIUS Surgical Theatre at University Hospital Tübingen is Europe's
first ceiling-mounted, high-field intraoperative MRI. The system gives
neurosurgeons improved on-demand access to real-time and high
resolution diagnostic quality MR imaging and data at any point during a
procedure without moving the patient. The surgeon can visualize,
evaluate and confirm results while modifying treatment without case
interruption which may lead to improved outcomes and enhanced patient
Szerlip NJ et al. Transsphenoidal resection of sellar tumors using
high-field intraoperative magnetic resonance imaging. Skull Bas.
Bellut D et al. Impact of intraoperative MRI-guided transsphenoidal
surgery on endocrine function and hormone substitution therapy in
patients with pituitary adenoma. Swiss Med Wkly 2012;142:w13699.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre - a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. VISIUS Surgical Theatres
serve the neurosurgical, cardiovascular and cerebrovascular markets and
have been selected by leading medical institutions around the world.
IMRIS VISIUS® Surgical Theatre at University Hospital Tübingen
Image with caption: "IMRIS VISIUS® Surgical Theatre at University Hospital Tübingen (CNW Group/IMRIS Inc.)". Image available at: http://photos.newswire.ca/images/download/20130612_C7499_PHOTO_EN_27917.jpg
SOURCE: IMRIS Inc.
For further information: